BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shin WG, Lee SW, Baik GH, Huh KC, Lee SI, Chung JW, Jung WT, Park MI, Jung HK, Kim HU. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. Helicobacter. 2016;21:266-278. [PMID: 26470999 DOI: 10.1111/hel.12279] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Lim H, Bang CS, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial. Medicine (Baltimore) 2018;97:e13245. [PMID: 30431605 DOI: 10.1097/MD.0000000000013245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kim JW. The Effects of Probiotics on the Treatment of Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2016;16:129. [DOI: 10.7704/kjhugr.2016.16.3.129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kim BJ, Yang CH, Song HJ, Jeon SW, Kim GH, Kim HS, Kim TH, Shim KN, Chung IK, Park MI, Choi IJ, Kim JH, Kim BW, Baik GH, Han SW, Seo HE, Jung WT, Hwan Oh J, Kim SG, Lee JH, Park SK, Park BJ, Yang BR, Lee J, Kim JG. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success. Helicobacter. 2019;24:e12646. [PMID: 31368629 DOI: 10.1111/hel.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
4 Gong EJ, Ahn JY. Antimicrobial Resistance of Helicobacter pylori Isolates in Korea. Korean J Helicobacter Up Gastrointest Res 2018;18:82. [DOI: 10.7704/kjhugr.2018.18.2.82] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
5 Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22. [PMID: 28940815 DOI: 10.1111/hel.12441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
6 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 238] [Article Influence: 68.5] [Reference Citation Analysis]
7 Jung JH, Cho IK, Lee CH, Song GG, Lim JH. Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Helicobacter pylori Infection. Gut Liver 2018;12:165-72. [PMID: 29212313 DOI: 10.5009/gnl17177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fraser AG. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. Aliment Pharmacol Ther 2017;46:550-1. [DOI: 10.1111/apt.14198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Lee KH, Park SY, Jeong SJ, Jung DH, Kim JH, Jeong SH, Kang IM, Song YG. Can Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori. Infect Chemother 2019;51:10-20. [PMID: 30941933 DOI: 10.3947/ic.2019.51.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci 2020;35:e33. [PMID: 32030921 DOI: 10.3346/jkms.2020.35.e33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
11 O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017;22 Suppl 1. [PMID: 28891137 DOI: 10.1111/hel.12410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
12 Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter. 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
13 Gweon TG, Kim JS, Kim BW. An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment. Gut Liver 2018;12:648-54. [PMID: 30037167 DOI: 10.5009/gnl18079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
14 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
15 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Lee H, Kim BJ, Kim SG, Kim JI, Choi IJ, Lee YC, Kim JG, Kim JJ; Korean College of Helicobacter and Upper Gastrointestinal Research. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. Trials. 2017;18:549. [PMID: 29149904 DOI: 10.1186/s13063-017-2281-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
18 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, Kim Y, Yoo JJ, Seo WW, Lee HS, Shin WG. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut 2021:gutjnl-2020-323845. [PMID: 33975868 DOI: 10.1136/gutjnl-2020-323845] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Reference Citation Analysis]
21 Huh CW, Youn YH, Jung da H, Park JJ, Kim JH, Park H. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. PLoS One 2016;11:e0162258. [PMID: 27588679 DOI: 10.1371/journal.pone.0162258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
22 Jang JH, Kim JY, Mun YC, Bang SM, Lim YJ, Shin DY, Choi YB, Yhim HY, Lee JW, Kook H; on the behalf of Korean Aplastic Anemia Working Party. Management of immune thrombocytopenia: Korean experts recommendation in 2017. Blood Res 2017;52:254-63. [PMID: 29333401 DOI: 10.5045/br.2017.52.4.254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
23 Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
24 Lim JH, Kim SG, Song JH, Hwang JJ, Lee DH, Han JP, Hong SJ, Kim JH, Jeon SW, Kim GH, Shim KN, Shin WG, Kim TH, Kim SM, Chung IK, Kim HS, Kim HU, Lee J, Kim JG. Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease. Gut Liver 2017;11:226-31. [PMID: 27609487 DOI: 10.5009/gnl16099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
25 Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114. [PMID: 28497487 DOI: 10.1111/apt.14130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 11.8] [Reference Citation Analysis]
26 Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
27 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Reference Citation Analysis]
28 Seo SI, Do BJ, Kang JG, Kim HS, Jang MK, Kim HY, Shin WG. Helicobacter pylori Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance. J Clin Med 2019;9:E54. [PMID: 31881688 DOI: 10.3390/jcm9010054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
29 Kwon YH, Jeon SW, Nam SY, Lee HS, Park JH. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019;24:e12585. [PMID: 30969459 DOI: 10.1111/hel.12585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Lee BE, Kim JS, Kim BW, Kim JH, Kim JI, Chung JW, Jeon SW, Lee JH, Kim JH, Kim N, Lee JY, Seo SY, Park SY, Kim SE, Joo MK, Song HJ, Kim KB, Bang CS, Kim HJ. Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years. Helicobacter 2021;26:e12780. [PMID: 33596342 DOI: 10.1111/hel.12780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, Moon CM, Kim SE, Jung HK, Jung SA. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol 2017;17:16. [PMID: 28109257 DOI: 10.1186/s12876-017-0579-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
32 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol. 2019;34:700-706. [PMID: 30011083 DOI: 10.1111/jgh.14383] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
33 Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy. Korean J Gastroenterol 2019;73:26. [DOI: 10.4166/kjg.2019.73.1.26] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
34 Park JS, Park JE, Oh BS, Yoon BW, Kim HK, Lee JW, Kim NH, Cho WS, Woo YS, Jahng J, Kim YS. [Trend in the Eradication Rates of Helicobacter pylori Infection Over the Last 10 Years in West Gyeonggi-do, Korea: A Single Center Experience]. Korean J Gastroenterol 2017;70:232-8. [PMID: 29161792 DOI: 10.4166/kjg.2017.70.5.232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Choi YK, Ahn JY, Won SH, Jung K, Na HK, Jung KW, Kim DH, Lee JH, Choi KD, Song HJ, Lee GH, Jung H. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study. Journal of Gastroenterology and Hepatology 2019;34:1696-702. [DOI: 10.1111/jgh.14639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
36 Lee YD, Kim SE, Park SJ, Park MI, Moon W, Kim JH, Jung K, Song J. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection. Korean J Gastroenterol 2020;76:142-9. [PMID: 32969362 DOI: 10.4166/kjg.2020.76.3.142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]